<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Immunology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Immunology</journal-title><trans-title-group xml:lang="ru"><trans-title>Russian Journal of Immunology</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-7221</issn><issn publication-format="electronic">2782-7291</issn><publisher><publisher-name xml:lang="en">Russian Society of Immunology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">191</article-id><article-id pub-id-type="doi">10.31857/S102872210006939-7</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">HUMAN RECOMBINANT ANTI-MULLERIAN HORMONE: A SELF-ACTIVATING DRUG</article-title><trans-title-group xml:lang="ru"><trans-title>РЕКОМБИНАНТНЫЙ АНТИМЮЛЛЕРОВ ГОРМОН ЧЕЛОВЕКА: ЛЕКАРСТВО, СПОСОБНОЕ К САМОАКТИВАЦИИ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rak</surname><given-names>A. Ya.</given-names></name><name xml:lang="ru"><surname>Рак</surname><given-names>А. Я.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Junior Researcher of the Protein Biochemistry Laboratory;</p><p>PhD student,</p><p>St. Petersburg</p></bio><bio xml:lang="ru"><p>м. н. с. лаборатории биохимии белка ФГУП «Государственный научно-ис сле до ва тель ский институт особо чистых биопрепаратов»;</p><p>аспирант,</p><p>197110 Санкт-Петербург, ул. Пудожская, д. 7,</p></bio><email>a.ya.rak@hpb.spb.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Trofimov</surname><given-names>A. V.</given-names></name><name xml:lang="ru"><surname>Трофимов</surname><given-names>А. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Group Head of the Protein Biochemistry Laboratory,</p><p>St. Petersburg</p></bio><bio xml:lang="ru"><p>руководитель группы лаборатории биохимии белка,</p><p>Санкт-Петербург</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ischenko</surname><given-names>A. M.</given-names></name><name xml:lang="ru"><surname>Ищенко</surname><given-names>А. М.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, Head of the Protein Biochemistry Laboratory,</p><p>St. Petersburg</p></bio><bio xml:lang="ru"><p>к. б. н., начальник лаборатории биохимии белка,</p><p>Санкт-Петербург</p></bio><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">State Research Institute for Highly Pure Biopreparations</institution></aff><aff><institution xml:lang="ru">ФГУП «Государственный научно-исследовательский институт особо чистых биопрепаратов» ФМБА России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Saint-Petersburg State University</institution></aff><aff><institution xml:lang="ru">Санкт-Петербургский Государственный Университет</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2019-04-15" publication-format="electronic"><day>15</day><month>04</month><year>2019</year></pub-date><volume>22</volume><issue>2-1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>486</fpage><lpage>488</lpage><history><date date-type="received" iso-8601-date="2020-05-12"><day>12</day><month>05</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-05-12"><day>12</day><month>05</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2019, Rak A.Y., Trofimov A.V., Ischenko A.M.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2019, Рак А.Я., Трофимов А.В., Ищенко А.М.</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="en">Rak A.Y., Trofimov A.V., Ischenko A.M.</copyright-holder><copyright-holder xml:lang="ru">Рак А.Я., Трофимов А.В., Ищенко А.М.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://rusimmun.ru/jour/article/view/191">https://rusimmun.ru/jour/article/view/191</self-uri><abstract xml:lang="en"><p>Here, the autoproteolytic activity of human recombinant anti-Mullerian hormone (rAMH), a potential antineoplastic drug, was investigated. It was shown that the hormone is not only able to activate itself by the limited proteolysis, but also specifically interacts with the proteolytic inhibitor aprotinin. The involvement of the rAMH specific proteolysis site in interaction with a specifi c receptor type II (MISRII) was found. The data obtained may be useful to clarify some aspects of the native AMH biochemistry and pharmacodynamics of the recombinant hormone.</p></abstract><trans-abstract xml:lang="ru"><p>В работе исследована аутопротеолитическая активность рекомбинантного антимюллерова гормона (рАМГ) человека – потенциального противоопухолевого лекарственного средства. Показано, что гормон не только способен к самоактивации посредством ограниченного протеолиза, но и специфически взаимодействует с протеолитическим ингибитором апротинином. Также установлено участие сайта специфического протеолиза рАМГ во взаимодействии со специфическим рецептором II типа, что может прояснить некоторые аспекты биохимии природного АМГ и фармакодинамики рекомбинантного гормона.</p></trans-abstract><kwd-group xml:lang="en"><kwd>AMH</kwd><kwd>anti-mullerian hormone</kwd><kwd>autoproteolysis</kwd><kwd>MIS</kwd><kwd>MISRII</kwd><kwd>antineoplastic drug</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>АМГ</kwd><kwd>антимюллеров гормон</kwd><kwd>аутопротеолиз</kwd><kwd>MISRII</kwd><kwd>противоопухолевый препарат</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. MacLaughlin D. T., Donahoe P. K.Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers. Future Oncol. 2010, 6(3), 391–405.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Jung Y. S., Kim H. J., Seo S. K., Choi Y. S., Nam E. J., Kim S. W., Han H. D., Kim J. W., Kim Y. T. Anti-proliferative and apoptotic activities of Müllerian inhibiting substance combined with calcitriol in ovarian cancer cell lines. Yonsei Med J. 2016, 57(1), 33–40.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Di Clemente N., Jamin S. P., Lugovskoy A., Carmillo P., Ehrenfels C., Picard J. Y., Whitty A., Josso N., Pepinsky R. B., Cate R. L. Processing of anti-mullerian hormone regulates receptor activation by a mechanism distinct from TGF-β. Mol Endocrinol. 2010, 24(11), 2193–2206.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. Rak A. Ya., Trofi mov A. V., Protasov E. A., Rodin S. V., Zhakhov A. V., Zabrodskaya Ya. A., Ischenko A. M. Spontaneous proteolytic processing of human recombinant anti-mullerian hormone: structural and functional differences of the molecular forms. Appl Biochem Microbiol. 2019, 55(1),13–20.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. Рак А. Я., Трофимов А. В., Колобов А. А., Ищенко А. М. Моноклональные антитела против С-концевого фрагмента рекомбинантного антимюллерова гормона человека: инструмент для очистки, детекции и исследования. Цитокины и воспаление. 2018, 17(1–4), 72–79.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6. Rak A. Ya., Trofimov A. V., Pigareva N. V., Simbirtsev A. S., Ischenko A. M. The cytotoxic effect of activated recombinant anti-mullerian hormone as a basis for the development of a new drug. Cell Tissue Biol. 2018, 12(6), 460–467.</mixed-citation></ref></ref-list></back></article>
